Arcellx, Inc. (ACLX) Stock Price, News, Quote & History - Yahoo …
Find the latest Arcellx, Inc. (ACLX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Arcellx, Inc. (ACLX) Latest Stock News & Headlines - Yahoo Finance
Get the latest Arcellx, Inc. (ACLX) stock news and headlines to help you in your trading and investing decisions.
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and …
May 10, 2024 · Arcellx Inc (NASDAQ:ACLX), a trailblazer in the field of cell therapy, disclosed its financial outcomes for the first quarter ended March 31, 2024. The company's detailed financial performance was ...
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
6 days ago · Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - Yahoo …
Nov 7, 2024 · Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
ACLX May 2025 130.000 put (ACLX250516P00130000) Stock Price, …
Find the latest ACLX May 2025 130.000 put (ACLX250516P00130000) stock quote, history, news and other vital information to help you with your stock trading and investing.
Arcellx (ACLX) Surged in Q3. Here’s Why - Yahoo Finance
Nov 1, 2024 · "Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company focused on cell therapies for multiple myeloma. Shares contributed this quarter after the company confirmed that data from its iMMagine-1 ...
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Nov 7, 2024 · aclx Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago.
Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business …
Nov 13, 2023 · Arcellx Inc (NASDAQ:ACLX) announces promising updates on CART-ddBCMA trial with median follow-up of 22 months. Financials show $482.7 million in cash reserves, funding operations into 2026.
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Feb 29, 2024 · Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Some results have been removed